"LAA Occluder PREVAILs in Cost-Effectiveness" - Nicole Lou
Percutaneous left atrial appendage closure with the Watchman device was cost-saving in the long-term, even after accounting for the uptick in stroke risk observed in one trial, according to researchers at the Icahn School of Medicine at Mount Sinai. Compared against non-vitamin K antagonist oral anticoagulants, LAA occlusion was a better value by year five. “Despite the increased risk of ischemic stroke observed in the PREVAIL trial, LAA closure is cost-effective and cost saving relative to NOACs and warfarin when the full body of RCT data is taken into consideration,” said Vivek Reddy, MD, director of cardiac arrhythmia services at The Mount Sinai Hospital. He added, “LAA closure with the Watchman device is an economically viable stroke risk reduction strategy for patients with AF seeking an alternative to lifelong anticoagulation.”
— Vivek Reddy, MD, Director, Cardiac Arrhythmia Services, The Mount Sinai Hospital, The Leona M. and Harry B. Helmsley Charitable Trust Professor, Medicine, Cardiac Electrophysiology, Icahn School of Medicine at Mount Sinai
Researchers Discover Rare Cortical Neurons That Can Help Put the Brain to Sleep
Sep 11, 2026 View All Press Releases
A Promising Study Suggests a Blood Test Could Spot Alzheimer’s Early in Progression
Apr 21, 2026 View All Press Releases
New Research Reveals Autism Risk Genes Are Shared Across Ancestries
Mar 30, 2026 View All Press Releases
